CA2681565C - Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery - Google Patents

Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery Download PDF

Info

Publication number
CA2681565C
CA2681565C CA2681565A CA2681565A CA2681565C CA 2681565 C CA2681565 C CA 2681565C CA 2681565 A CA2681565 A CA 2681565A CA 2681565 A CA2681565 A CA 2681565A CA 2681565 C CA2681565 C CA 2681565C
Authority
CA
Canada
Prior art keywords
composition
interferon alpha
methionine
miu
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2681565A
Other languages
English (en)
French (fr)
Other versions
CA2681565A1 (en
Inventor
John M. Docherty
Marianna Foldvari
Praveen Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altum-Avro Pharma Partnership
Original Assignee
Helix Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Biopharma Corp filed Critical Helix Biopharma Corp
Publication of CA2681565A1 publication Critical patent/CA2681565A1/en
Application granted granted Critical
Publication of CA2681565C publication Critical patent/CA2681565C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
CA2681565A 2007-03-30 2008-03-27 Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery Active CA2681565C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90932407P 2007-03-30 2007-03-30
US60/909,324 2007-03-30
PCT/CA2008/000563 WO2008119160A1 (en) 2007-03-30 2008-03-27 Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery

Publications (2)

Publication Number Publication Date
CA2681565A1 CA2681565A1 (en) 2008-10-09
CA2681565C true CA2681565C (en) 2016-10-25

Family

ID=39807744

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2681565A Active CA2681565C (en) 2007-03-30 2008-03-27 Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery

Country Status (18)

Country Link
US (3) US8945529B2 (enExample)
EP (1) EP2134353B1 (enExample)
JP (1) JP5587762B2 (enExample)
KR (1) KR20090130081A (enExample)
AU (1) AU2008234364B2 (enExample)
CA (1) CA2681565C (enExample)
CY (1) CY1118794T1 (enExample)
DK (1) DK2134353T3 (enExample)
ES (1) ES2617063T3 (enExample)
HR (1) HRP20170250T1 (enExample)
HU (1) HUE033256T2 (enExample)
LT (1) LT2134353T (enExample)
MX (1) MX2009010405A (enExample)
PL (1) PL2134353T3 (enExample)
PT (1) PT2134353T (enExample)
SI (1) SI2134353T1 (enExample)
TW (1) TWI440477B (enExample)
WO (1) WO2008119160A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008900B1 (fr) * 2013-07-25 2018-03-30 Centre Nat Rech Scient Nanoparticules lipidiques multicompartimentees
US8986732B2 (en) * 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US10159646B2 (en) 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
ES2952779T3 (es) 2017-05-18 2023-11-06 Modernatx Inc ARN mensajero modificado que comprende elementos de ARN funcionales
EP3630067A4 (en) * 2017-05-26 2021-08-11 Altum Pharmaceuticals Inc. GIVING A BIPHASIC CANNABINOID
EP3714048B1 (en) 2017-11-22 2025-04-09 ModernaTX, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
WO2019104160A2 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
EP3849595B1 (en) 2018-09-13 2025-11-19 ModernaTX, Inc. Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
US20220401584A1 (en) 2018-09-14 2022-12-22 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
KR20220070246A (ko) 2019-09-23 2022-05-30 디디에스 리서치 인크. 침투 증진제를 갖는 지질 소포 조성물
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
MX2023011157A (es) 2021-03-24 2024-01-25 Glo Pharma Inc Peptidos y metodos para reducir la pigmentacion de la piel.
US20240376445A1 (en) 2021-06-22 2024-11-14 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
KR20240102989A (ko) * 2021-11-04 2024-07-03 글로 파마, 인크. 화장품 적용을 위한 방법 및 조성물
MA71619A (fr) 2022-07-26 2025-05-30 Modernatx, Inc. Polynucléotides modifiés pour la régulation temporelle de l'expression
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
CA2168260C (en) 1993-07-28 2000-04-11 Marianna Foldvari Biphasic multilamellar lipid vesicles
IN184589B (enExample) 1996-10-16 2000-09-09 Alza Corp
US5993852A (en) * 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
US6656499B1 (en) * 1999-11-12 2003-12-02 Pharmaderm Laboratories, Ltd. Composition for transdermal and dermal administration of interferon-α
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile

Also Published As

Publication number Publication date
EP2134353A4 (en) 2013-08-07
PL2134353T3 (pl) 2017-06-30
WO2008119160A1 (en) 2008-10-09
AU2008234364B2 (en) 2013-10-17
KR20090130081A (ko) 2009-12-17
SI2134353T1 (sl) 2017-03-31
DK2134353T3 (en) 2017-02-20
US20130216610A1 (en) 2013-08-22
PT2134353T (pt) 2017-02-15
TW200846030A (en) 2008-12-01
US20130224283A1 (en) 2013-08-29
HUE033256T2 (hu) 2017-11-28
LT2134353T (lt) 2017-03-27
ES2617063T3 (es) 2017-06-15
AU2008234364A1 (en) 2008-10-09
US8945529B2 (en) 2015-02-03
CY1118794T1 (el) 2017-07-12
JP2010522698A (ja) 2010-07-08
US20100196453A1 (en) 2010-08-05
EP2134353B1 (en) 2016-11-16
TWI440477B (zh) 2014-06-11
MX2009010405A (es) 2010-02-03
EP2134353A1 (en) 2009-12-23
JP5587762B2 (ja) 2014-09-10
HRP20170250T1 (hr) 2017-04-07
CA2681565A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
EP2134353B1 (en) Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
US5853755A (en) Biphasic multilamellar lipid vesicles
KR0157428B1 (ko) 비 전달용 지질부형제와 그 사용법
EP0711148B1 (en) Biphasic multilamellar lipid vesicles
EP2515865A2 (en) Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
WO1991001719A1 (en) Topical delivery of peptides/proteins entrapped in dehydration/rehydration liposomes
HUP0101026A2 (hu) Parenterálisan alkalmazható, liposzóma alapú diszperziós eritropoietin készítmények
EP3238746A1 (en) High-density lipoprotein, and delivery of drug to posterior segment of eye by ocular instillation of said cytophilic peptide-fused high-density lipoprotein
EP1265638A1 (en) Compositions for transdermal and transmucosal administration of therapeutic agents
US10159646B2 (en) Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US20130085146A1 (en) Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
CA2957641C (en) Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intra vaginal delivery
Foldvari et al. Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
HK1135913B (en) Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
HK1135913A (en) Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
JPH10316555A (ja) 高分子化合物を含有するリポソーム外用剤
TW202007398A (zh) 減少關節內類固醇的併發症之方法
TW202519194A (zh) 用於疼痛控制之關節內皮質類固醇的微脂體組成物
CN121731479A (zh) 七叶皂苷钠或其异构体作为渗透促进剂的应用
JP2023537474A (ja) 疼痛制御のための関節内コルチコステロイドの医薬組成物
JPWO1991007962A1 (ja) 脂肪乳剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130319

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251022

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260205